Pyxis Oncology initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Pyxis Oncology with a Buy rating and $4 price target. The company has a multi-modality portfolio consisting of early- and mid-clinical stage candidates, the analyst tells investors in a research note. The firm believes Pyxis at the current valuation of $69M, with three clinical assets and a revenue potential of $606M by 2033, is undervalued and an attractive opportunity for a long-term investor.